Biogen Inc. $BIIB Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC lifted its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 132.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 784,863 shares of the biotechnology company’s stock after buying an additional 446,845 shares during the period. Fisher Asset Management LLC’s holdings in Biogen were worth $177,285,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Russell Investments Group Ltd. increased its holdings in shares of Biogen by 1,524.5% in the third quarter. Russell Investments Group Ltd. now owns 2,175,055 shares of the biotechnology company’s stock worth $491,301,000 after acquiring an additional 2,041,161 shares in the last quarter. Eurizon Capital SGR S.p.A. raised its position in shares of Biogen by 179.3% during the third quarter. Eurizon Capital SGR S.p.A. now owns 286,567 shares of the biotechnology company’s stock worth $64,730,000 after purchasing an additional 183,973 shares during the period. CENTRAL TRUST Co lifted its holdings in shares of Biogen by 3,271.3% during the 3rd quarter. CENTRAL TRUST Co now owns 5,765 shares of the biotechnology company’s stock valued at $1,302,000 after purchasing an additional 5,594 shares in the last quarter. Fifth Third Bancorp grew its position in shares of Biogen by 1,086.4% in the 3rd quarter. Fifth Third Bancorp now owns 389,633 shares of the biotechnology company’s stock valued at $88,010,000 after purchasing an additional 356,792 shares during the period. Finally, New Mexico Educational Retirement Board increased its stake in Biogen by 1,707.3% during the 3rd quarter. New Mexico Educational Retirement Board now owns 130,556 shares of the biotechnology company’s stock worth $29,490,000 after purchasing an additional 123,332 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Price Performance

Shares of Biogen stock opened at $253.40 on Monday. The business’s 50 day simple moving average is $233.35 and its 200 day simple moving average is $205.04. Biogen Inc. has a 52-week low of $160.36 and a 52-week high of $261.00. The firm has a market cap of $37.46 billion, a PE ratio of 108.29, a P/E/G ratio of 2.87 and a beta of 0.10. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.37 and a current ratio of 1.95.

Biogen (NASDAQ:BIIB – Get Free Report) last released its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, beating the consensus estimate of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The firm had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.63 billion. During the same quarter in the previous year, the business posted $4.81 EPS. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. On average, analysts predict that Biogen Inc. will post 12.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

BIIB has been the topic of several research analyst reports. Seaport Research Partners upgraded shares of Biogen to an “outperform” rating in a report on Monday, October 12th. Robert W. Baird increased their price objective on shares of Biogen from $250.00 to $290.00 and gave the stock an “outperform” rating in a research report on Thursday, October 29th. Needham & Company LLC raised their price objective on shares of Biogen from $256.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Argus raised shares of Biogen from a “hold” rating to a “buy” rating and set a $280.00 price objective on the stock in a research report on Thursday, October 29th. Finally, Canaccord Genuity Group boosted their price objective on shares of Biogen from $248.00 to $272.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Biogen presently has an average rating of “Moderate Buy” and an average price target of $254.41.

View Our Latest Research Report on Biogen

About Biogen

(Free Report)

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

Read More

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.